• Publications
  • Influence
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
The outcome of a workshop that considered the methodology and design of magnetic resonance studies is reported, recommending how this new tool might best be used.
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
CA4P produces rapid changes in the vasculature of human tumors that can be assessed using PET measurements of tumor perfusion, and these changes were seen at 24 hours in spleen or kidney.
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m2; these are doses at which tumor blood flow reduction has been recorded, and the only toxicity that possibly was related to the drug dose up to 40 mg/ m2 was tumor pain.
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
The ability to measure tumor response to antiproliferative treatment with [(18)F]FLT and PET and other than phosphorylation in tumors, [(18]F] FLT was found to be metabolically stable in vivo.
The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels
This study shows that in vivo [18F]FLT kinetics depend on TK1 protein expression and has the potential to yield specific information on tumour proliferation in diagnostic imaging and therapy monitoring.
Metabolic activation of temozolomide measured in vivo using positron emission tomography.
The purpose of this research was to quantitate and confirm the mechanism of in vivo metabolic activation of temozolomide. The secondary aims were to evaluate the tumor, normal tissue, and plasma
In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography
[18F]FETA shows hypoxia-dependent tumour retention and is, thus, a promising PET marker that warrants clinical evaluation.
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
The tumor-specific, molecularly targeted effects demonstrated by this second-generation antisense oligonucleotide (ASO) directed against survivin mRNA underpin confirmatory studies evaluating its therapeutic efficacy in cancer.
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents, and the recommended phase II dose is from 11 to 14 mg/m2.
First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*
The first human imaging studies on the EXPLORER scanner using a range of different protocols that provide initial evidence in support of claims that the scanner is sufficient to cover the entire human adult body in a single acquisition in more than 99% of the population.